Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.
Institutional and Insider Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Ernexa Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | N/A | N/A | -$14.08 million | ($26.20) | -0.17 |
| Profound Medical | $18.81 million | 13.50 | -$42.57 million | ($1.24) | -5.64 |
Ernexa Therapeutics has higher earnings, but lower revenue than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ernexa Therapeutics and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -263.74% | -151.16% |
| Profound Medical | -206.76% | -78.88% | -64.06% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Ernexa Therapeutics and Profound Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 574.16%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 71.67%. Given Ernexa Therapeutics’ higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Profound Medical.
Summary
Ernexa Therapeutics beats Profound Medical on 6 of the 11 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
